AEON Net Income Applicable To Common Shares from 2010 to 2026
| AEON Stock | 0.95 0.09 8.65% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -47.3 M | Current Value -44.9 M | Quarterly Volatility 95.3 M |
Check AEON Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AEON Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 0.0 or Depreciation And Amortization of 82.9 K, as well as many indicators such as Price To Sales Ratio of 21.27, Dividend Yield of 0.0 or Days Sales Outstanding of 23.22. AEON financial statements analysis is a perfect complement when working with AEON Biopharma Valuation or Volatility modules.
AEON | Net Income Applicable To Common Shares | Build AI portfolio with AEON Stock |
Evaluating AEON Biopharma's Net Income Applicable To Common Shares across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into AEON Biopharma's fundamental strength.
Latest AEON Biopharma's Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of AEON Biopharma over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. AEON Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AEON Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
AEON Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | 59,711,601 | |
| Coefficient Of Variation | 159.68 | |
| Mean Deviation | 91,022,822 | |
| Median | 137,081,000 | |
| Standard Deviation | 95,346,259 | |
| Sample Variance | 9090.9T | |
| Range | 192.7M | |
| R-Value | (0.85) | |
| Mean Square Error | 2699.6T | |
| R-Squared | 0.72 | |
| Significance | 0.000016 | |
| Slope | (16,039,255) | |
| Total Sum of Squares | 145454.5T |
AEON Net Income Applicable To Common Shares History
About AEON Biopharma Financial Statements
AEON Biopharma investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how AEON Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -47.3 M | -44.9 M |
Pair Trading with AEON Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AEON Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AEON Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against AEON Stock
| 0.81 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.74 | KURA | Kura Oncology | PairCorr |
| 0.73 | ABP | Abpro Holdings | PairCorr |
| 0.71 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.7 | GNLX | Genelux Common | PairCorr |
The ability to find closely correlated positions to AEON Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AEON Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AEON Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AEON Biopharma to buy it.
The correlation of AEON Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AEON Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AEON Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AEON Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of AEON Biopharma Correlation against competitors. To learn how to invest in AEON Stock, please use our How to Invest in AEON Biopharma guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could AEON diversify its offerings? Factors like these will boost the valuation of AEON Biopharma. If investors know AEON will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AEON Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate AEON Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating AEON Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause AEON Biopharma's market price to deviate significantly from intrinsic value.
Understanding that AEON Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AEON Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, AEON Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.